Trials / Completed
CompletedNCT00036257
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-461 |
Timeline
- Start date
- 2002-03-01
- Completion
- 2003-04-01
- First posted
- 2002-05-09
- Last updated
- 2011-10-17
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00036257. Inclusion in this directory is not an endorsement.